Reading view
Test-Time Strategies for More Efficient and Accurate Agentic RAG
Red-Teaming Vision-Language-Action Models via Quality Diversity Prompt Generation for Robust Robot Policies
Reinforcement Learning for Diffusion LLMs with Entropy-Guided Step Selection and Stepwise Advantages
Multiscale Structure-Guided Latent Diffusion for Multimodal MRI Translation
Competition-Aware CPC Forecasting with Near-Market Coverage
A mathematical theory for understanding when abstract representations emerge in neural networks
A Decision-Theoretic Formalisation of Steganography With Applications to LLM Monitoring
Causality Is Key to Understand and Balance Multiple Goals in Trustworthy ML and Foundation Models
DriveMind: A Dual Visual Language Model-based Reinforcement Learning Framework for Autonomous Driving
Robust Fine-Tuning from Non-Robust Pretrained Models: Mitigating Suboptimal Transfer With Epsilon-Scheduling
RobotArena $\infty$: Scalable Robot Benchmarking via Real-to-Sim Translation
Retrofitters, pragmatists and activists: Public interest litigation for accountable automated decision-making
SpaceControl: Introducing Test-Time Spatial Control to 3D Generative Modeling
IROSA: Interactive Robot Skill Adaptation using Natural Language
Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future Directions
Cancers (Basel). 2026 Feb 28;18(5):800. doi: 10.3390/cancers18050800.
ABSTRACT
BACKGROUND AND OBJECTIVE: Liquid biopsy has transformed the management of advanced prostate cancer, yet its clinical role in non-metastatic disease remains uncertain. Conventional biomarkers such as PSA, imaging, and pathology have limited ability to capture minimal residual disease and biological aggressiveness. The objective of this review was to critically evaluate the current evidence on circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-metastatic prostate cancer, focusing on feasibility, prognostic value, and potential clinical applications.
METHODS: A narrative review of PubMed-indexed original studies evaluating liquid biopsy in clinically localized or non-metastatic prostate cancer was performed. Eligible studies included patients treated with curative-intent local therapy or experiencing biochemical recurrence without radiologic metastases. Study designs were predominantly prospective or retrospective observational cohorts. Liquid biopsy analytes included CTCs and ctDNA assessed from peripheral blood plasma using EpCAM-based enrichment, targeted next-generation sequencing, whole-genome sequencing, or ultra-sensitive tumor-informed assays. Primary outcomes included detection rates, associations with clinicopathologic features, biochemical recurrence, metastasis-free survival, and overall survival. Key Findings and Limitations: Across 11 studies, CTC detection using EpCAM-based platforms was infrequent in localized disease and biochemical recurrence and showed limited prognostic value (10-11% in preoperative settings). In contrast, ctDNA was detectable in a minority of patients but consistently identified biologically aggressive disease and a higher risk of recurrence when present, particularly using tumor-informed ultra-sensitive assays. Limitations include low detection rates, heterogeneous methodologies, small sample sizes, and predominantly exploratory study designs.
CONCLUSIONS AND CLINICAL IMPLICATIONS: Currently, its most promising application is not broad screening, but as a selective, biology-driven tool for detecting minimal residual disease and refining risk assessment. CtDNA acts as a biological risk modifier, potentially guiding the escalation or de-escalation of adjuvant therapy. However, prospective biomarker-driven trials are required to validate these strategies before routine clinical implementation.
PMID:41827734 | PMC:PMC12984391 | DOI:10.3390/cancers18050800
The FBI is investigating malware hidden inside games hosted on Steam
A deep-time landscape of plant cis-regulatory sequence evolution
Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies
Cell Death Discovery, Published online: 12 March 2026; doi:10.1038/s41420-026-02996-1
Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies